Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mystic Miss Not Make Or Break For Imfinzi

Nov 16 2018

• By Kevin Grogan

Fortune — Mystic message not good news for AstraZeneca • Source: Shutterstock

Related Content

Roche's Tecentriq Positive But Not Perfect In IMpower130 First-line Lung Cancer Study

Oct 23 2018

ARCTIC Chill Descends On AstraZeneca's Imfinzi/Treme Combo In NSCLC

Apr 24 2018

AstraZeneca's PACIFIC Update Bolsters Imfinzi's Lead In Stage III Lung Cancer

Sep 26 2018

MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC

Jul 27 2017

Related Companies

AstraZeneca PLC

Merck & Co., Inc.

Additional Topics

Clinical Trials Companies ImmunoOncology Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.